Relevant products have passed the preliminary stage test

On January 17, according to the official micro signal disclosure of China biology, China biology Shanghai Jienuo Biotechnology Co., Ltd. (Zhongsheng Jienuo) and Shenzhen Mindray Biomedical Electronics Co., Ltd. (Mindray medical) recently reached a strategic cooperation to jointly develop a chemiluminescence detection kit for neutralizing antibody of immune effect of new crown vaccine, so as to provide a reliable detection means for effect evaluation after vaccination.

With the popularization of vaccination, the effectiveness of vaccination has always attracted much attention, and vaccine effect evaluation has become a new topic in the industry. The cooperation between the two companies mainly focuses on the field of "vaccine immune effect evaluation".

It is reported that the two sides will cooperate in four detection paths based on the antibody level after immunization with the new crown vaccine, namely:

Determination of neutralizing antibody after immunization with neocrown vaccine

Determination of total anti antibody after immunization with neocrown vaccine

Determination of Sigg antibody after immunization with neocrown vaccine

Determination of RBD IgG antibody after immunization with new crown vaccine

In fact, the detection of neutralizing antibody is a reliable index for the evaluation of vaccine effect.

At present, the new crown vaccine Immune Effect Evaluation Kit jointly developed by Zhongsheng Jienuo and Mindray has passed the validation test of a large number of samples at different stages of vaccination. At the same time, Zhongsheng Jienuo also developed a new crown vaccine neutralizing antibody detection kit based on enzyme-linked immunosorbent assay and virus neutralization test method.

Diagnostic reagent business enterprise of China biology

According to the enterprise investigation, Sinopharm Group Shanghai Jienuo Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Jienuo") is subordinate to China Pharmaceutical Group Corporation (hereinafter referred to as "Sinopharm group") and China Biotechnology Co., Ltd. (hereinafter referred to as "China biology"), which is a diagnostic reagent business enterprise of China biology, Professional agent sales of medical devices and in vitro diagnostic reagents at home and abroad.

The 13th five year strategic plan of China's biology will vigorously develop six core sectors: vaccines, blood products, animal vaccines, diagnostic reagents, medical beauty and antibodies. Shanghai Jienuo's in vitro diagnostic reagent is one of the key development sectors of the 13th five year plan, and it is also the first company to lead the reform of biological mixed ownership in China.

In 2017, Shanghai Zeno won the technology transfer authorization cooperation project of cervical cancer risk assessment methylation test kit of oncgnostics in Germany and 2smart single tube multiple nucleic acid test kit of Pathfinder in the Netherlands. While acting as an agent for the import of kits, it is also preparing to build its own production plant to transform its detection technology into the ground.

Shanghai Jienuo is positioned as the world's leading technology industrialization transformation platform in the field of IVD. Its products focus on multiple detection of infectious disease pathogens and molecular diagnosis of tumors, mainly including methylation detection kit for cervical cancer risk assessment, nucleic acid detection kit for single tube multiple pathogens of respiratory tract, encephalitis / meningitis, intestine, central nervous system, eugenics and reproductive tract infection, etc, It serves major clinical hospitals, centers for Disease Control and prevention, inspection and quarantine bureaus, etc.

In early 2020, it developed a New Coronavirus nucleic acid detection kit for COVID-19 and sent it to China CDC for verification at the first time. The first batch was listed in the work guide of the National Health Commission and became one of the three recommended supply enterprises; The first batch has obtained the registration certificate of New Coronavirus nucleic acid test kit issued by the State Administration of drug control.

Mairui layout veterinary medical devices

On November 6, 2020, enterprise investigation showed that Mindray medical established a new animal medical technology company, which is fully known as "Shenzhen Mindray Animal Medical Technology Co., Ltd", with a registered capital of 200 million yuan, and the legal representative and chairman are Li Xiting.

According to shengshida medical observation, the company's business address is located in Longhua District, Shenzhen. Its industry is special equipment manufacturing. Its business scope includes: general business items: R & D, sales and technical services of veterinary medical devices, consumables and biological products.

The licensed business items are: the production of veterinary medical devices, consumables and biological pro

ducts. The current operation status of Shenzhen Mindray Animal Medical Technology Co., Ltd. is survival (in operation, opening and registered).

In this field, Mindray has previously launched animal blood analyzer and other products. At present, the purchase demand of medical devices in pet medical institutions continues to grow, which may explain this trend of Mindray.

Cultivate minimally invasive surgery, orthopedics, ultra-high-end color Doppler ultrasound and other businesses

According to Mindray's announcement, it has 17 subsidiaries and more than 40 branches in China, and has formed a global R & D, marketing and service network. The main products cover three areas: life information and support, in vitro diagnosis and medical imaging.

In the field of life information and support, the products include a series of instruments and solutions for life information monitoring and support, such as monitors, defibrillators, anesthesia machines, respirators, electrocardiographs, operating beds, operating lamps, hanging towers, suspension bridges, infusion pumps, and overall solutions for operating rooms / intensive care units (or / ICUs), as well as surgical endoscopic camera systems, cold light sources It is a series of minimally invasive surgical products including pneumoperitoneum machine, optical endoscope, minimally invasive surgical instruments and surgical consumables.

In the field of in vitro diagnosis, the company provides a series of fully automatic and semi-automatic in vitro diagnosis products for laboratories, clinics and hospitals, mainly including blood cell analyzer, biochemical analyzer, chemiluminescence immunoanalyzer, coagulation analyzer, urine analyzer, microbial diagnosis system and related reagents through human samples (such as blood, body fluid Obtain clinical diagnostic information through the detection of tissue, etc.

In the field of medical imaging, the company's products include ultrasonic diagnosis system and digital X-ray imaging system. The ultrasonic diagnosis system provides real-time diagnostic images by using the digitally controlled acoustic wave transmitting and receiving technology. It can detect the ultrasonic echo characteristics, blood flow direction, velocity, hardness and other information of human tissues.

Facing the future post epidemic era, the announcement pointed out that R & D investment in automation and intelligent assembly line in the field of in vitro diagnosis, respiratory machine sub business in the field of microbial sub business and life information and support, and interconnection of in-hospital monitoring will be increased.

Mindray pointed out that it will continue to actively cultivate businesses such as minimally invasive surgery, orthopedics, molecular diagnosis and ultra-high-end color Doppler ultrasound, and accelerate R & D in these fields by combining internal and external R & D.